相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Jefferies analysts identify neuroinflammation as one of the most important emerging storylines in Parkinson's disease drug development, with key milestones expected heading into 2027. - The addressable early Parkinson's population across the US and EU is projected to exceed two million patients by 2035, representing a potential disease-modifying therapy market approaching $8 billion. - BioVie's bezisterim reported positive Phase 2 topline data showing improvements in blood-based inflammatory markers and clinical outcomes, with patients having higher baseline inflammation seeing the greatest benefit. - Jefferies contends that Parkinson's is driven by multiple mechanisms—alpha-synuclein, cellular cleanup breakdown, and neuroinflammation—meaning single-pathway drugs alone are unlikely to succeed.
- Rudolph Tanzi and Reisa Sperling are leading a shift toward Alzheimer's prevention, with the fully enrolled AHEAD 3-45 trial testing lecanemab in cognitively normal individuals with elevated amyloid, results expected in the late 2020s. - A 2026 Annals of Neurology review supports combination disease-modifying therapy using repurposed drugs including GLP-1 receptor agonists, iron chelators, and chemical chaperones across multiple neurodegenerative targets. - More than 150 therapies are now in nearly 200 clinical trials targeting at least 17 different biological processes, with blood-based biomarkers like plasma pTau217 enabling earlier patient identification and trial enrichment. - Real-world data from the Alzheimer's Association's ALZ-NET shows significant functional benefits on daily activities within six months of treatment, while the U.S. POINTER trial found lifestyle interventions improved cognition in at-risk older adults.
- Protego Biopharma secured $130 million in Series B funding led by Novartis Venture Fund and Forbion to advance PROT-001 into late-stage clinical testing for AL amyloidosis. - The experimental drug PROT-001 takes a novel approach by binding to and stabilizing misfolded proteins before they accumulate, rather than clearing existing toxic deposits like previous failed therapies. - An early-stage study began in Q2 2024 with results expected next year, while a Phase 2/3 trial is planned for the second half of 2026. - The approach builds on research from Scripps professor Jeffery Kelly, who co-founded FoldRx and discovered the protein stabilizing drug Vyndamax, now generating billions in sales for Pfizer.
- Bristol-Myers Squibb has exercised its option on Prothena's PRX005, a tau-targeting antibody for Alzheimer's disease, in a deal potentially worth $2.2 billion with $55 million upfront. - PRX005 specifically targets the microtubule-binding region of tau protein, which correlates more closely with dementia stages than other tau regions according to cerebrospinal fluid analysis. - The antibody completed phase 1 single ascending dose studies showing safety and effective central nervous system penetration, with multiple ascending dose results expected by year-end. - This move makes PRX005 the centerpiece of BMS's neuroscience pipeline, marking the company's return to Alzheimer's drug development after previous exits from the field.
- Genentech, a Roche subsidiary, announced its decision to advance prasinezumab into Phase III development for early-stage Parkinson's disease based on encouraging Phase IIb PADOVA study results. - The investigational anti-alpha-synuclein antibody demonstrated clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease patients during the Phase IIb trial and longer-term follow-up. - Prasinezumab represents a potential first-in-class treatment targeting alpha-synuclein, marking a significant milestone in Parkinson's disease drug development.
• Cognition Therapeutics' Phase 2 SHINE study demonstrates that Alzheimer's patients with lower p-tau217 levels showed 95% improvement on ADAS-Cog 11 and 108% better MMSE scores with zervimesine treatment versus placebo. • Dr. Mary Hamby, VP of Research at Cognition, will co-host a precision medicine workshop at the Neuroimmunology Drug Development Summit, focusing on optimizing patient selection for clinical trials. • The company's findings suggest plasma p-tau217 could serve as a simple blood-based biomarker to identify Alzheimer's patients most likely to benefit from beta amyloid-targeted therapies.
- Prothena's Phase 3 AFFIRM-AL trial evaluates birtamimab in Mayo stage 4 AL amyloidosis patients, targeting a survival benefit with a p-value threshold of 0.10 per FDA agreement. - Approximately 80% of trial participants are receiving daratumumab as standard of care, with researchers expecting mortality trends similar to previous VITAL trial observations. - The company estimates 16,000 diagnosed and treated AL amyloidosis patients in the US, highlighting significant market potential for an anti-amyloid therapy that directly clears amyloid from vital organs.
- Inhibikase Therapeutics discontinues development of risvodetinib for Parkinson's disease after Phase II trial fails to show significant efficacy despite meeting safety endpoints. - While the drug showed modest improvements in specific measures, including a 1.41-point improvement in MDS-UPDRS Part 2 scores at 100mg dosage, it failed to meet the primary functional endpoints. - The company will pivot to focus on IkT-001Pro for pulmonary arterial hypertension, marking another setback in the challenging landscape of Parkinson's drug development.
- The European Medicines Agency's (EMA) CHMP supports Leqembi's approval for early Alzheimer's, reversing its earlier negative opinion. - The recommendation is limited to patients with mild cognitive impairment or mild dementia due to Alzheimer's, who have one or no copies of the ApoE ε4 gene. - This genetic profile represents 60-80% of the Alzheimer's population in Europe, potentially justifying Leqembi's price and reimbursement. - The approval comes with a caveat for measures to reduce the risk of ARIA, a side effect involving brain swelling and microbleeding.
- Research in the seven major markets (7MM) increasingly prioritizes disease-modifying therapies (DMTs) and treatments for non-motor symptoms of Parkinson's disease. - 66% of the 93 products in Phase I-III development are prospective neuroprotective agents or DMTs targeting mechanisms like alpha-synuclein aggregation and neuroinflammation. - 26% of pipeline DMTs target alpha-synuclein aggregation, though this approach has faced setbacks, highlighting the complexity of Parkinson's pathogenesis. - There is also growing research into treatments for non-motor symptoms, with 3% of the pipeline specifically targeting Parkinson's disease dementia and psychosis.
